Baseline characteristics of study subjects
| . | HIV uninfected . | HIV acute . | HIV progressor . | ART treated . | HIV controllers . |
|---|---|---|---|---|---|
| No. of patients | 29 | 8 | 42 | 10 | 35 |
| Sex, male/female ratio | 1.6 | 1/0 | 3.2 | 2.33 | 4.8 |
| Race | |||||
| White, n | 29 | 7 | 28 | 7 | 25 |
| African American, n | — | 1 | 8 | 1 | 10 |
| Asian, n | — | — | 1 | 1 | — |
| Other, n | — | — | 5 | 1 | — |
| Viral load, RNA copies/mL, average (range) | N/A | 61 383 (4 290-191 000) | 104 473(4 350-10 000 001) | < 50 | 86(49-203) |
| CD4 count, cells/μL, average ± SD | N/A | 566 ± 173 | 390 ± 203 | 717 ± 317 | 1028 ± 273 |
| . | HIV uninfected . | HIV acute . | HIV progressor . | ART treated . | HIV controllers . |
|---|---|---|---|---|---|
| No. of patients | 29 | 8 | 42 | 10 | 35 |
| Sex, male/female ratio | 1.6 | 1/0 | 3.2 | 2.33 | 4.8 |
| Race | |||||
| White, n | 29 | 7 | 28 | 7 | 25 |
| African American, n | — | 1 | 8 | 1 | 10 |
| Asian, n | — | — | 1 | 1 | — |
| Other, n | — | — | 5 | 1 | — |
| Viral load, RNA copies/mL, average (range) | N/A | 61 383 (4 290-191 000) | 104 473(4 350-10 000 001) | < 50 | 86(49-203) |
| CD4 count, cells/μL, average ± SD | N/A | 566 ± 173 | 390 ± 203 | 717 ± 317 | 1028 ± 273 |